Eton Pharmaceuticals (ETON) Change in Receivables (2020 - 2025)

Eton Pharmaceuticals has disclosed Change in Receivables across 6 years of filings, most recently posting -$1.3 million for Q4 2025.

• Change in Receivables for Q4 2025 came in at -$1.3 million, down 241.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $6.4 million (up 105.13% YoY), and the FY2025 annual result was $6.4 million, up 105.13% from the prior year.
• Change in Receivables came in at -$1.3 million for Q4 2025 at Eton Pharmaceuticals, up from -$1.4 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $11.0 million in Q1 2025 to a low of -$4.7 million in Q1 2022.
• The 5-year median for Change in Receivables is $303000.0 (2021), against an average of $643850.0.
• Across the five-year window, Change in Receivables jumped 10495.83% in 2021 and slumped 1955.16% in 2022, its largest moves.
• Eton Pharmaceuticals' Change in Receivables stood at $5.1 million in 2021, then plunged by 93.04% to $354000.0 in 2022, then tumbled by 123.73% to -$84000.0 in 2023, then soared by 1217.86% to $939000.0 in 2024, then slumped by 241.11% to -$1.3 million in 2025.
• The last three Change in Receivables figures came in at -$1.3 million (Q4 2025), -$1.4 million (Q3 2025), and -$1.9 million (Q2 2025), per Business Quant data.